Alpha Tau Medical Ltd. (NASDAQ:DRTSW – Get Rating) saw a large decrease in short interest in December. As of December 30th, there was short interest totalling 28,700 shares, a decrease of 24.1% from the December 15th total of 37,800 shares. Based on an average trading volume of 32,200 shares, the days-to-cover ratio is presently 0.9 days.
Alpha Tau Medical Trading Up 8.5 %
Alpha Tau Medical stock traded up $0.03 during midday trading on Friday, hitting $0.43. The stock had a trading volume of 12,588 shares, compared to its average volume of 32,317. The firm's fifty day moving average is $0.29 and its two-hundred day moving average is $0.43. Alpha Tau Medical has a 52-week low of $0.18 and a 52-week high of $1.06.
Get
Alpha Tau Medical alerts:
Institutional Investors Weigh In On Alpha Tau Medical
Several hedge funds and other institutional investors have recently added to or reduced their stakes in DRTSW. Goldman Sachs Group Inc. purchased a new stake in Alpha Tau Medical in the 1st quarter worth approximately $42,000. Chicago Partners Investment Group LLC bought a new position in Alpha Tau Medical in the 1st quarter worth approximately $55,000. Jane Street Group LLC bought a new position in Alpha Tau Medical in the 1st quarter worth approximately $64,000. Whitebox Advisors LLC bought a new position in Alpha Tau Medical in the 3rd quarter worth approximately $65,000. Finally, Walleye Trading LLC bought a new position in Alpha Tau Medical in the 1st quarter worth approximately $65,000.
About Alpha Tau Medical
(Get Rating)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers.
See Also
- Get a free copy of the StockNews.com research report on Alpha Tau Medical (DRTSW)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
阿爾法頭醫療有限公司(納斯達克代碼：DRTSW-GET Rating)看到空頭股數在12月份大幅下降。截至12月30日，空頭股數共有28,700股，比12月15日的37,800股減少了24.1%。以32,200股的平均成交量計算，目前天數與回補比率為0.9天。
Alpha Tau醫療交易上漲8.5%
Alpha Tau Medical的股票在週五午盤交易中上漲0.03美元，觸及0.43美元。該股成交量為12,588股，而其平均成交量為32,317股。該公司的50日移動均線切入位為0.29美元，200日移動均線切入位為0.43美元。Alpha Tau Medical的52周低點為0.18美元，52周高點為1.06美元。
到達
Alpha Tau醫療公司警報：
機構投資者看好Alpha Tau Medical
幾家對沖基金和其他機構投資者最近增持或減持了DRTSW的股份。高盛股份有限公司在第一季度購買了阿爾法頭醫療公司價值約42,000美元的新股份。芝加哥合作夥伴投資集團有限責任公司在第一季度購買了Alpha Tau Medical的一個新頭寸，價值約5.5萬美元。建恩街集團有限責任公司在第一季度購買了阿爾法頭醫療公司的一個新頭寸，價值約64,000美元。Whitebox Advisors LLC在第三季度購買了Alpha Tau Medical的一個新頭寸，價值約65,000美元。最後，Walleye Trading LLC在第一季度購買了Alpha Tau Medical的一個新頭寸，價值約6.5萬美元。
關於Alpha Tau Medical
(獲取評級)
Alpha Tau醫療有限公司是一家臨床階段的腫瘤治療公司，在以色列和美國從事用於治療實體癌症的擴散阿爾法放射療法(Alpha DART)的研究、開發和商業化。其Alpha-DART技術用於皮膚癌、口腔癌、胰腺癌和乳腺癌的臨床試驗，以及肝細胞癌、肺癌和前列腺癌的臨床前研究。
另請參閱
- 免費獲取StockNews.com關於Alpha Tau Medical(DRTSW)的研究報告
- 市場回顧周-1/16-1/20
- Old Dominion是否表明Trucking正在踩剎車？
- 諾德斯特龍對零售業降價的擔憂
- 埃克森美孚股票：在Buy Point附近
- 高股息率的必和必拓認為中國推動了23年的增長
獲得Alpha Tau醫學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Alpha Tau Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。
